Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Intensified Radiation Therapy with Nivolumab vs Standard Radiation Therapy with Cisplatin in Early-Stage, HPV-Positive Oropharyngeal Cancer
NCT03952585Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-free Survival at 4.6 years and MD Anderson Dysphagia Inventory Global Quality of Life Score at 2 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03952585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952585.